Palatin Technologies, Inc.
Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026
Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential…
